Boston Scientific recently secured the European CE marking of its Vercise Neural Navigator 5 Software, a key component of the company’s Deep Brain Stimulation (DBS) system for Parkinson’s disease treatment. The rapid expansion and innovation in digital health technologies, coupled with developments like Boston Scientific’s new DBS system, signals a positive shift in patient care. The CE marking of the company’s software is particularly notable, reflecting a major leap in integrating advanced technologies for more precise and effective management of neurological disorders, according to GlobalData, a leading data and analytics company.

According to GlobalData, the market for neurological devices was valued at $12.5 billion in 2023 and is expected to grow by a compound annual growth rate (CAGR) of 4.60% to reach $20.9 billion by 2033. This growth underscores the increasing importance and demand for advanced diagnostic and monitoring technologies in neurology, including those targeting Parkinson’s disease.

Cynthia Stinchcombe, Medical Devices Analyst at GlobalData, comments: “The market for neurological devices is witnessing significant growth and diversification. CE marking for Boston Scientific’s software highlights the increasing integration of advanced technology in the management of neurological disorders, fitting into the broader industry shift towards precision medicine, as reflected in the FDA’s recent push for innovative solutions in Parkinson’s disease management.”

GlobalData projects that with the continuous advancements in technology and the introduction of innovative therapies, the landscape of neurological devices is set to transform, offering new hope to millions affected by neurological diseases such as Parkinson’s.

Stinchcombe adds: “The CE marking of Boston Scientific’s Vercise Neural Navigator 5 Software underscores a significant enhancement in treatment capabilities for Parkinson’s disease, emphasizing the crucial role of innovative medical technologies in contemporary healthcare. As the landscape of medical treatment evolves, particularly with the integration of such sophisticated systems, we are seeing a promising shift towards more personalized and effective treatment strategies for neurological conditions.”

GlobalData’s analysis reflects the recent emphasis on wearable technologies and digital health apps—such as those leveraging Apple Watch data to monitor Parkinson’s symptoms—indicating a parallel innovation trajectory. While wearable technologies facilitate continuous monitoring outside clinical settings, sophisticated tools like Boston Scientific’s software enhance therapeutic interventions, offering a holistic approach to disease management.

Stinchcombe concludes: “In the face of an aging population and a rising incidence of Parkinson’s disease, the advancements that are being witnessed are encouraging for those affected. As the industry continues to focus on both proven and novel solutions, technologies like Boston Scientific’s DBS system are pivotal in broadening the horizons of neurology diagnostics and improving patient outcomes. Together with the FDA’s initiative to enhance AI-driven diagnostics, these advancements are poised to dramatically improve the landscape of neurology, enhancing both diagnostics and patient outcomes significantly.”